Anika Therapeutics, Inc.
ANIK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $119,907 | $120,792 | $113,827 | $147,794 |
| % Growth | -0.7% | 6.1% | -23% | – |
| Cost of Goods Sold | $43,909 | $38,260 | $40,607 | $64,851 |
| Gross Profit | $75,998 | $82,532 | $73,220 | $82,943 |
| % Margin | 63.4% | 68.3% | 64.3% | 56.1% |
| R&D Expenses | $25,544 | $21,763 | $18,321 | $27,327 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $55,555 | $59,925 | $51,229 | $74,096 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$21,095 |
| Operating Expenses | $81,099 | $81,688 | $69,550 | $80,328 |
| Operating Income | -$5,101 | $844 | $3,670 | $2,615 |
| % Margin | -4.3% | 0.7% | 3.2% | 1.8% |
| Other Income/Exp. Net | $2,337 | $2,312 | $654 | -$188 |
| Pre-Tax Income | -$2,764 | $3,156 | $4,324 | $2,427 |
| Tax Expense | $6,064 | $6,595 | $2,124 | -$1,707 |
| Net Income | -$56,385 | -$82,667 | -$14,859 | $4,134 |
| % Margin | -47% | -68.4% | -13.1% | 2.8% |
| EPS | -3.83 | -5.64 | -1.02 | 0.29 |
| % Growth | 32.1% | -452.9% | -451.7% | – |
| EPS Diluted | -3.83 | -5.64 | -1.02 | 0.28 |
| Weighted Avg Shares Out | 14,721 | 14,656 | 14,561 | 14,401 |
| Weighted Avg Shares Out Dil | 14,721 | 14,656 | 14,561 | 14,634 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $2,312 | $654 | – |
| Interest Expense | – | $0 | $0 | – |
| Depreciation & Amortization | $8,121 | $14,217 | $14,487 | $14,317 |
| EBITDA | $3,020 | $15,061 | $18,157 | -$4,163 |
| % Margin | 2.5% | 12.5% | 16% | -2.8% |